ValiRx PLC Virtual AGM Access
June 20 2023 - 1:00AM
RNS Non-Regulatory
TIDMVAL
ValiRx PLC
20 June 2023
20 June 2023
ValiRx PLC ("ValiRx" or the "Company")
Virtual AGM Access
London, UK - ValiRx Plc (AIM: VAL), a life science company
focusing on early-stage cancer therapeutics and women's health,
announces today an update regarding virtual access to the upcoming
Annual General Meeting ("AGM").
In addition to welcoming shareholders to attend the AGM
in-person at The Walbrook Building, 25 Walbrook, London, EC4N 8AF,
a live webcast of the AGM presentation including Q&A will be
made available. Commencing at 11:00am (UK time) on 28 June 2023,
investors and analysts are invited to join via registration at
https://brrmedia.news/VAL_AGM23 .
The recording of the webcast will also be available for playback
from the Company's website, www.valirx.com, shortly after the
event.
The Directors of the Company take responsibility for this
announcement.
*** ENDS ***
For more information, please contact:
ValiRx plc Tel: +44 (0) 2476 796496
www.valirx.com
Dr Suzanne Dilly, CEO Suzanne.Dilly@valirx.com
V Formation (Public Relations) +44 (0) 115 787 0206
www.vformation.biz
Lucy Wharton - Senior PR Executive
Sue Carr - Director lucy@vformation.biz
sue@vformation.biz
--------------------------
Cenkos Securities plc (Joint Broker) Tel: +44 (0) 20 7397
8900
Dale Bellis/Michael Johnson (Sales)
Callum Davidson/Giles Balleny (Corporate
Finance)
--------------------------
Turner Pope Investments (Joint Broker) Tel: +44 (0) 20 3657
James Pope / Andy Thacker 0050
--------------------------
Notes for Editors
About ValiRx
ValiRx is a life science company focused on early-stage cancer
therapeutics and women's health, accelerating the translation of
innovative science into impactful medicines to improve patient
lives.
ValiRx provides the scientific, financial, and commercial
framework for enabling rapid translation of innovative science into
clinical development.
Using its extensive and proven experience in research and drug
development, the team at ValiRx selects and incubates promising
novel drug candidates and guides them through an optimised process
of development, from pre-clinical studies to clinic and
investor-ready assets.
ValiRx connects diverse disciplines across scientific,
technical, and commercial domains, with the aim of achieving a more
streamlined, less costly, drug development process. The team works
closely with carefully selected collaborators and leverages the
combined expertise required for science to advance.
Lead candidates from ValiRx's portfolio are outlicensed or
partnered with investors through ValiRx subsidiary companies for
further clinical development and commercialisation.
ValiRx listed on the AIM Market of the London Stock Exchange in
October 2006 and trades under the ticker symbol: VAL.
For further information, visit: www.valirx.com
This communication is a "Reach" announcement. Reach is a
non-regulatory news service. By using this service an issuer is
confirming that the information contained in this announcement is
of a non-regulatory nature. Information required to be notified
under the AIM Rules for Companies, Market Abuse Regulation or other
regulation would be disseminated as an RNS regulatory announcement
and not on RNS Reach.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAGPURWQUPWGMB
(END) Dow Jones Newswires
June 20, 2023 02:00 ET (06:00 GMT)
Valirx (LSE:VAL)
Historical Stock Chart
From Sep 2024 to Oct 2024
Valirx (LSE:VAL)
Historical Stock Chart
From Oct 2023 to Oct 2024